Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol’s Opdivo/Yervoy Combo In Lung Cancer: Dosing Tweaks Improve Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

But development plan needs to change for patients who are PD-L1 negative.


Related Content

Roche's Oncology Strategy: The Long Game Comes Into Focus
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers


Related Companies